Spider's Orange Colors Both Lure Prey and Frighten Predators
Spotted coin spider colors are a Swiss army knife of deception, bringing food closer, and keeping assailants at bay. (Source: The Scientist)
Source: The Scientist - April 22, 2019 Category: Science Tags: News & Opinion Source Type: news

Longitudinal associations between life satisfaction and cannabis use initiation, cessation, and disorder symptom severity in a cohort of young Swiss men - Deligianni ML, Studer J, Daeppen JB, Gmel G, Bertholet N.
This study aims to assess whether life satisfaction (SWLS) at age 21 is ... (Source: SafetyLit)
Source: SafetyLit - April 22, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

FEFU scientists are developing brand-new method to heal brain cancer
(Far Eastern Federal University) Scientists from Far Eastern Federal University (FEFU) in cooperation with colleagues from Blokhin Russian Cancer Research Center (Moscow), Switzerland, and Sweden for the first time studied proteins, which constitute WNT signaling pathway of the cancer stem cells of glioblastoma multiforme (GBM CD133+ CSCs), one of the most aggressive brain tumors. Researchers revealed a number of proteins, which are potential targets to attack during complex antitumor therapy. A related article was published in Oncology Reports. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 22, 2019 Category: Biology Source Type: news

Do Hospitals Have Flu's Spread Under Control?
FRIDAY, April 19, 2019 -- Many hospital workers and patients spread the flu before they show any symptoms, a new study says. The bottom line: Current flu infection control measures in hospitals may be inadequate, the Swiss researchers say. " Our... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2019 Category: General Medicine Source Type: news

'Revived' dead pig brains offer new research hopes
Ethicists fear research animals could end up in a 'grey-area - not alive, but not completely dead' Related items fromOnMedica Report helps explain Gulf War illness One in two women and one in three men will develop neurological disease NICE sets care standards for spasticity ‘Suicide tourism’ to Switzerland doubles in four years Head injuries linked to Alzheimer ’s and other disorders (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 18, 2019 Category: UK Health Source Type: news

Switzerland to monitor potential health risks posed by 5G networks
Switzerland will introduce a monitoring system to assuage concerns about the potential health impact of fifth-generation (5G) mobile frequency emissions and smooth the cutting-edge technology's rollout, the government said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche reports a strong start in 2019 and raises the outlook for the full-year
Group sales increase 8% at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor (Source: Roche Media News)
Source: Roche Media News - April 17, 2019 Category: Pharmaceuticals Source Type: news

Roche reports a strong start in 2019 and raises the outlook for the full-year
Group sales increase 8% at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor (Source: Roche Investor Update)
Source: Roche Investor Update - April 17, 2019 Category: Pharmaceuticals Source Type: news

Is an R & amp;D Race Driving the Surgical Robotics Market?
Robotic-assisted surgery has emerged with an attempt to overcome the limitations of traditional minimally invasive surgical procedures. With increasing competition, the way to gain market share in this quickly growing market is with innovative technology. This means R&D is at the forefront of this market, driving adoption, expanding applications, and leading to a market that will more than double in size by 2025. It’s been a steady trajectory since the first medical robot, Arthrobot, was developed in Canada in 1983 for use during orthopedic procedures1. Then, the first robotic-assisted procedure, neur...
Source: MDDI - April 16, 2019 Category: Medical Devices Authors: Yulia Sorokina and Jeff Wong Tags: R & D Orthopedics Source Type: news

Hospital nursing staff may ‘spread flu before symptoms appear’
A substantial proportion of hospital patients and healthcare workers shed the influenza virus before the appearance of clinical symptoms, according to Swiss researchers who examined flu transmission. (Source: Nursing Times)
Source: Nursing Times - April 16, 2019 Category: Nursing Source Type: news

Study advocates using hand rub with three steps for 15 seconds
Applying hand rub with three steps for 15 seconds is as effective at reducing bacteria as the six steps for 30 seconds recommended by the World Health Organization, according to Swiss researchers. (Source: Nursing Times)
Source: Nursing Times - April 16, 2019 Category: Nursing Source Type: news

This newsletter was not written by a robot*
Bots are becoming an inevitable part of newsgathering. Two women are determined to prevent them becoming an inevitable part of warfare*although it ’s a bit stilted in placesIn a week in whichrobot journalists won new customers and admirers in Britain, you ’ll be reassured to note that the Guardian is still relying on human beings, for the Upside series at least.And very busy they were, investigating hopeful stories that all involved David-and-Goliath struggles, albeit in very different fields.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 12, 2019 Category: Science Authors: Mark Rice-Oxley Tags: Media Newspapers Astronomy Switzerland The far right Science Space Robots Artificial intelligence (AI) Food Work & careers Access to water Ireland World news UK news Source Type: news

Reminder: Invitation to Roche's First Quarter Sales 2019 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2019 prior to the opening of the Swiss Stock Exchange on Wednesday, April 17th, 2019 (Source: Roche Investor Update)
Source: Roche Investor Update - April 11, 2019 Category: Pharmaceuticals Source Type: news

Scientists identify a key gene in the transmission of deadly African sleeping sickness
Life scientists from UCLA and the University of Bern have identified a key gene in the transmission of African sleeping sickness — a severe disease transmitted by the bite of infected tsetse flies, which are common in sub-Saharan Africa.The disease is fatal if untreated, as the parasite responsible moves from the bloodstream to the central nervous system. Tens of millions of people in 36 African countries are at risk. There is no vaccine, and conventional drug treatments, which include an arsenic derivative, are antiquated, not very effective and have severe side effects.The research,  published in the journal N...
Source: UCLA Newsroom: Health Sciences - April 10, 2019 Category: Universities & Medical Training Source Type: news

Spinoff Complete: Alcon Now Stands on Its Own
Novartis has completed the spinoff of Alcon, an eye-care company it acquired nearly a decade ago for $12.9 billion. The Basel, Switzerland-based company first announced the planned separation in June of last year. The spinout was completed through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (ADR), with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on April 8, 2019, at the close of business. The newly spun-out company is performing extremely well on the market. Alcon’s ADR (were trading at $57.81 leaving the company to be val...
Source: MDDI - April 9, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Alcon/Novartis: eye inflection
The Swiss pharma group’s former subsidiary will fare better alone (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 9, 2019 Category: Pharmaceuticals Source Type: news

Novartis completes spinout of Alcon eye biz
Novartis (NYSE:NVS) closed the spinout of its Alcon vision care business, setting the stage for its shares to begin trading today in Switzerland and New York. The spinout, announced last June, saw each Novartis shareholder receive a single ALC share for every five NVS shares as of the close of business April 1, Novartis said last month. “For more than 70 years, Alcon has been dedicated to helping people see brilliantly and now, as an independent company, we are pursuing even more opportunities to further that mission,” CEO David Endicott said in prepared remarks. “We are poised to achieve sustainable...
Source: Mass Device - April 9, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Mergers & Acquisitions Vision Wall Street Beat Alcon Novartis Source Type: news

Circus performer is BALD after a rare condition caused her to pull out every strand of hair
Claire Jenna Ory, 24, of Bristol, developed trichotillomania at just ten years old when the stress of starting a new school in her native Switzerland left her with a bald patch. (Source: the Mail online | Health)
Source: the Mail online | Health - April 8, 2019 Category: Consumer Health News Source Type: news

New Vein Access Device Could Benefit Nurses and DIVAs Alike
Schaffhausen, Switzerland-based Physeon is trying to bring its Veinplicity device to the U.S. market. The device is designed to make veins easier to access on the first stick, preventing patients from being treated as pincushions. "Patients only deserve to be stuck one time," Physeon CEO Patrick Kullmann told MD+DI.  The Veinplicity device stands to nurses and patients with difficult intravenous access (DIVAs). The company recently selected Mayo Clinic as the U.S. trial site for Veinplicity with Gregory Schears, MD, serving as the principal investigator. The VIVA tr...
Source: MDDI - April 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: IV Products Source Type: news

Novartis, Amgen in dispute over migraine drug partnership
Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself. (Source: Reuters: Health)
Source: Reuters: Health - April 4, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis sues Amgen over collaboration on migraine treatment Aimovig
Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market migraine prevention drug Aimovig, and keep the profits for itself. (Source: Reuters: Health)
Source: Reuters: Health - April 4, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Loop Medical lands $3.2M grant for blood collection device
Loop Medical said today that it has received a $3.2 million grant from the Bill & Melinda Gates Foundation to support pre-production and clinical trials required for the global registration of its blood collection device. The foundation had previously given the company a $400,000 grant. Based at the Swiss Institute of Technology (EPFL) in Lausanne, Switzerland, Loop Medical designed the device to be painless, easy-to-use and able to collect samples that are large enough for common high-throughput blood analyzers. The device was also designed to improve safety, particularly in countries with low medical resources. In th...
Source: Mass Device - April 4, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Blood Management Business/Financial News Featured Funding Roundup Laboratory Instruments/Laboratory Supplies News Well Research & Development Bill & Melinda Gates Foundation cerbahealthcare loopmedical swedishinstituteoftechnolo Source Type: news

Effectiveness of a workshop intervention on responsible reporting on suicide among Swiss media professionals - Scherr S, Markiewitz A, Arendt F.
OBJECTIVE: There is limited knowledge about the effects of a workshop intervention on responsible reporting on suicide (RRS) by media professionals. The study aimed to test how a workshop can shape reporting-relevant attitudes and beliefs among media profe... (Source: SafetyLit)
Source: SafetyLit - April 4, 2019 Category: International Medicine & Public Health Tags: Media, Marketing, and Internet Issues Source Type: news

Blocking epigenetic Swiss army knife may be a new strategy for treating colorectal cancer
(Van Andel Research Institute) A new study out today in Cancer Cell shows that blocking specific regions of a protein called UHRF1 switches on hundreds of cancer-fighting genes, impairing colorectal cancer cells' ability to grow and spread throughout the body. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 4, 2019 Category: Cancer & Oncology Source Type: news

Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal
Swiss pharmaceutical giant Roche has extended its tender offer for the outstanding shares of Philadelphia gene therapy company Spark Therapeutics to May 2. The $114.50 per share tender offer was set to expire at the end of the day on April 3. About 11.3 million shares of Spark (NASDAQ: ONCE), which represents about 29 percent of Sparks’s outstanding shares, had been validly tendered and received prior to the extension. Roche, which needs at least 50 percent of shares to be tendered to move forward… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 3, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Report: Drones are delivering blood samples in N.C.
Autonomous drones have begun to ferry blood samples between clinics and labs in the skies over North Carolina, according to a recent report from Wired. The drone service, run by UPS with drone technology from Matternet, made its first flight last Tuesday at Raleigh’s WakeMed Hospital, according to the report. The drone can carry up to five pounds and completes its flight in approximately three minutes, a significant reduction from the 30 minutes it would take for a driver to make the journey by car, according to Wired. While the drone is designed to work autonomously, all flights are monitored by a remote pilot-in-co...
Source: Mass Device - April 2, 2019 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Cardiac Assist Devices UPS Source Type: news

High throughput method to produce and screen engineered antimicrobial lanthipeptides
(University of Groningen) Nature has provided us with lots of antimicrobials. However, given the rapid increase of antimicrobial resistance, there is a need for the development of new-to-nature antibiotics. Lantibiotics are an interesting option. Molecular biologists from the University of Groningen and their colleagues in Switzerland and Germany have now developed a pipeline to create and screen large numbers of new lantibiotic peptides. The first results were published on April 1 in Nature Chemical Biology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 2, 2019 Category: Infectious Diseases Source Type: news

Characterization of Leachates from 6 Root Canal Sealers
Journal of EndodonticsPublication HistoryPublished online:March 21, 2019 AbstractIntroductionThe aim of this study was to evaluate 6 different endodontic sealers by characterizing their leachates and comparing their solubility in water over a 4-week period.MethodsThe solubility of each sealer (Apexit Plus [Ivoclar Vivadent AG, Schaan, Liechtenstein], MTA Fillapex [Angelus Dental, Londrina, Brazil], AH Plus [Dentsply DeTrey, Konstanz, Germany], BioRoot RCS [Septodont, Saint-Maur-des-Foss és, France], Total Fill [FKG Dentaire SA, La Chaux-de-Fonds, Switzerland], and Obturys [Itena, Paris, France]) was tested...
Source: Dental Technology Blog - April 1, 2019 Category: Dentistry Source Type: news

Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rules
Novartis AG must face a U.S. government lawsuit accusing it of paying millions of dollars in kickbacks to doctors so they would prescribe its drugs, after a federal judge ruled in a decision released on Monday that the government had offered evidence of a "company-wide kickback scheme." (Source: Reuters: Health)
Source: Reuters: Health - April 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Align Tech, ClearCorrect parent co Straumann bury the hatchet, ink distro deal
Align Technology (NSDQ:ALGN) said today that it inked a deal with competitor ClearCorrect parent company Straumann Holding to settle all outstanding patent disputes between the companies. The deal includes a $35 million payment from Switzerland-based Straumann, as well as a 5-year global distribution deal through which Straumann will distribute 5,000 of San Jose, Calif.-based Align Tech’s iTero Element scanners. The scanners will be integrated into the Straumann/Dental Wings Cares/DWOS workflow, Align Tech said in an SEC filing. Both companies agreed to dismiss all existing patent disputes between them...
Source: Mass Device - March 29, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Dental Featured Legal News Patent Infringement aligntechnology Straumann Holdings AG Source Type: news

David Attenborough Isn ’t Sure We Can Save the Natural World. But at 92, He’s Not Giving Up Trying
It’s the voice you notice first. In person, David Attenborough speaks in the same awestruck hush he has used in dozens of nature documentaries, a crisp half whisper that is often mimicked but seldom matched. Ninety-two years of use may have softened its edges, but still it carries the command of authority. Sitting in his home in the Richmond neighborhood of west London for one in a series of conversations, I feel compelled to drink a second cup of tea when he offers. It somehow seems wrong to say no. In his native U.K., Attenborough is held in the kind of esteem usually reserved for royalty. Over decades–first ...
Source: TIME: Science - March 28, 2019 Category: Science Authors: Dan Stewart Tags: Uncategorized Environment Source Type: news

Novartis MS drug wins FDA's blessing amid scrutiny of $88,000 annual price
Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Providence digital health spinout Xealth lands $11M funding round
Providence St. Joseph Health's spinout Xealth pulled in an $11 million Series A financing round to fuel expansion. The round was lead by California-based McKesson Ventures, the Swiss pharmaceutical company Novartis, health care and electronics company Philips and the California-based medical equipment company ResMed. Existing investors joining the round include Threshold Ventures, Providence Ventures, UPMC and Froedtert and the Medical College of Wisconsin health network. “With these new partners… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 27, 2019 Category: Biotechnology Authors: Coral Garnick Source Type: news

Novartis gets U.S. approval for new drug to treat multiple sclerosis
Novartis AG won U.S. Food and Drug Administration approval for its new multiple sclerosis drug Mayzent, as the Swiss drugmaker seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis new MS drug Mayzent to be priced at $88,000 per year
Novartis will price its new Mayzent multiple sclerosis drug at $88,000 dollars per year, the Swiss company's head of pharmaceuticals, Paul Hudson, said. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Swiss drugmaker Roche says to shutter Rio de Janeiro plant
Swiss drugmaker Roche will close its manufacturing plant in the Brazilian city of Rio de Janeiro, shuttering operations over the next five years before selling the plot, the company said in a statement on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Digital Health Startups Manager
Location: Penzberg, Germany Zug, Switzerland Job Type: Full-Time Employer: Roche As Digital Health Startups Manager you drive collaboration projects that have been initiated in the Creasphere accelerator program together with Life Cycle Team (LCT), R&D, Business Development (BD) and other functions until transfer into full solution development or co-marketing. (Source: eHealth News EU)
Source: eHealth News EU - March 26, 2019 Category: Information Technology Tags: Featured Jobs Source Type: news

Heat-health action plans to prevent heat-related deaths-experiences from Switzerland - Ragettli MS, R öösli M.
Since the record-breaking temperatures registered during summer 2003, cantonal health authorities in Switzerland have implemented measures to prevent adverse health effects from hot weather and heatwaves. Six cantons in the west of Switzerland and the cant... (Source: SafetyLit)
Source: SafetyLit - March 26, 2019 Category: International Medicine & Public Health Tags: Environmental Issues, Climate, Geophysics Source Type: news

3D printers have an ear for – making ears
(Natural News) A newly developed biomaterial is not just capable of being accepted by the body, but is also usable by 3D printers. Its Swiss creators demonstrated how the biocompatible hydrogel can be used to print artificial ears and other biomedical implants. The hydrogel is comprised of several biopolymers, including tiny crystals made from plant cellulose. When it is heated... (Source: NaturalNews.com)
Source: NaturalNews.com - March 26, 2019 Category: Consumer Health News Source Type: news

Spinal injuries in airborne accidents: a demographic overview of 148 patients in a Level-1 trauma center - B äcker HC, Vosseller JT, Benneker L, Noger M, Krause F, Hoppe S, Deml MC.
PURPOSE: The purpose of this study was to investigate the type and severity of spinal injury in airborne sports, as well as patients demographics in this unique set of athletes. Paragliding is one of the most popular airborne sports in Switzerland, which t... (Source: SafetyLit)
Source: SafetyLit - March 24, 2019 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Roche Sues U.S. Executives in Diabetes Test Strip Fight Roche Sues U.S. Executives in Diabetes Test Strip Fight
Roche is seeking tens of millions of dollars in a U.S. lawsuit against former executives of a Utah-based pharmacy company in the Swiss drugmaker's latest court case targeting what it calls fraudulent diabetes test strip schemes.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 23, 2019 Category: Pathology Tags: Diabetes & Endocrinology News Source Type: news

Novartis plans Alcon spinout for early April
Novartis (NYSE:NVS) said today that it’s planning to list the shares of its Alcon vision care business April 9 in Switzerland and New York. Terms for the spinout, announced last June, call for each Novartis shareholder to receive a single ALC share for every five NVS shares at the close of business April 8. The Swiss SIX exchange and the New York Stock Exchange have each approved the listing, Novartis said. “Alcon has secured debt financing of $3.5 billion through a group of banks. The Alcon credit rating will be investment-grade following the spin-off. Moody’s Investor Service and S&P Global Ratings ...
Source: Mass Device - March 22, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Mergers & Acquisitions Vision Wall Street Beat Alcon Novartis Source Type: news

New, exotic class of planets outside our solar system made out of GEMS
(Natural News) There are a lot of different types of planets in the universe. But the exoplanets recently identified by British and Swiss researchers are special because they contain large amounts of ruby and sapphire. This exotic class is made up of super-Earths, rocky planets that are bigger than our world. Formed in immense heat and found in close... (Source: NaturalNews.com)
Source: NaturalNews.com - March 22, 2019 Category: Consumer Health News Source Type: news

Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
CAMBRIDGE, Mass. and BASEL, Switzerland, March 21, 2019 -- (Healthcare Sales & Marketing Network) -- Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today announced ... Biopharmaceuticals, FDA Enzyvant, Roivant Sciences, Farber Disease, enzyme replacement therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2019 Category: Pharmaceuticals Source Type: news

Roche sues U.S. executives in fight over diabetes test strips
Roche is seeking tens of millions of dollars in damages and compensation in a U.S. lawsuit against former executives of a Utah-based company, the Swiss drugmaker's latest case targeting what it calls fraudulent schemes involving its diabetes test strips. (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Primex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN(R) in France
PARIS and ZUG, Switzerland, March 20, 2019 -- (Healthcare Sales & Marketing Network) -- Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative ... Biopharmaceuticals Primex Pharmaceuticals, Nordic Group, OZALIN (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2019 Category: Pharmaceuticals Source Type: news

Francoise Mornex is first female recipient of Heine H. Hansen Award [ELCC press release]
(European Society for Medical Oncology) The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2019 Heine H. Hansen (HHH) Award will be given to Francoise Mornex. The award will be presented at the ELCC 2019 (European Lung Cancer Congress), to be held 10-13 April in Geneva, Switzerland. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 20, 2019 Category: Cancer & Oncology Source Type: news

Alcon Powers Up Portfolio Ahead of Novartis Split
It's shaping up to be an interesting year for Alcon, which is expected to split from Novartis to become a standalone Switzerland-based company during the first half of 2019. Alcon just paid $285 million to acquire PowerVision and agreed to additional milestone-based payments starting in 2023. Fort Worth, TX-based PowerVision has been working to create fluid-based intraocular lens implants, but the new IOL technology won't be commercially available until after "significant additional development and clinical trials," Alcon noted. The new lens could prove to be well worth the wait, however, as it is designed to use...
Source: MDDI - March 18, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Implants Source Type: news

Can a lifetime guarantee boost value-based care?
Cheryl Bednar, 54, of Laflin, Penn., suffered from chronic pain from hip deterioration until Geisinger Dr. James Murphy performed a hip replacement in February 2018 and offered the lifetime guarantee. (Image from Geisinger) Swiss orthopedics company Medacta International and Geisinger Health System have said they will pilot a lifetime guarantee program for knee replacement surgeries. The program will cover full costs for screened Geisinger Health Plan members who receive knee replacement surgery while also ensuring reimbursement for any associated future care the patients may incur throughout their life...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Business/Financial News Featured Implants News Well Orthopedics Centers for Medicare and Medicaid Services (CMS) Geisinger Health System Medacta Source Type: news

Invitation to Roche's First Quarter Sales 2019 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2019 prior to the opening of the Swiss Stock Exchange on Wednesday, April 17th, 2019 (Source: Roche Investor Update)
Source: Roche Investor Update - March 18, 2019 Category: Pharmaceuticals Source Type: news